Tolmar Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   OVELIA · Ovarian Suppression Evaluating Subcutaneous Leuprolide…OVELIA · Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

   Primary and study completion pushed from Apr 30, 2026 to Nov 30, 2026

   Tolmar Inc.·Phase 3· NCT04906395· Registry history of NCT04906395 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.